Context Therapeutics (NASDAQ:CNTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a report released on Monday, Benzinga reports. HC Wainwright currently has a $6.00 target price on the stock.

Context Therapeutics Stock Performance

Shares of Context Therapeutics stock opened at $1.93 on Monday. Context Therapeutics has a one year low of $0.77 and a one year high of $2.75. The company has a market cap of $144.75 million, a price-to-earnings ratio of -1.45 and a beta of 2.31. The business’s 50 day moving average price is $2.31 and its 200 day moving average price is $1.90.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.04. On average, analysts predict that Context Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors have recently modified their holdings of CNTX. Great Point Partners LLC acquired a new stake in shares of Context Therapeutics in the second quarter valued at $14,876,000. Blue Owl Capital Holdings LP acquired a new position in Context Therapeutics during the 2nd quarter worth $10,348,000. Driehaus Capital Management LLC acquired a new position in Context Therapeutics during the 2nd quarter worth $4,527,000. Nantahala Capital Management LLC acquired a new position in Context Therapeutics during the 2nd quarter worth $3,881,000. Finally, Affinity Asset Advisors LLC grew its stake in Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.